Abstract
L-Mimosine, an iron chelator and a prolyl 4-hydroxylase inhibitor, blocks many cancer cells at the late G1 phase. B-cell translocation gene 2 (Btg2) regulates the G1/S transition phases of the cell cycle. N-myc downstream regulated gene 1 (Ndrg1) is a differentiation-inducing gene upregulated by hypoxia. We evaluated the molecular mechanisms of L-mimosine on cell cycle modulation in PC-3 and LNCaP prostate carcinoma cells. The effect of L-mimosine on cell proliferation of prostate carcinoma cells was determined by the [3H]thymidine incorporation and flow cytometry assays. L-Mimosine arrested the cell cycle at the G1 phase in PC-3 cells and at the S phase in LNCaP cells, thus attenuating cell proliferation. Immunoblot assays indicated that hypoxia and L-mimosine stabilized hypoxia-inducible factor-1α (HIF-1α) and induced Btg2 and Ndrg1 protein expression, but downregulated protein levels of cyclin A in both PC-3 and LNCaP cells. L-Mimosine treatment decreased cyclin D1 protein in PC-3 cells, but not in LNCaP cells. Dimethyloxalylglycine, a pan-prolyl hydroxylase inhibitor, also induced Btg2 and Ndrg1 protein expression in LNCaP cells. The transient gene expression assay revealed that L-mimosine treatment or cotransfection with HIF-1α expression vector enhanced the promoter activities of Btg2 and Ndrg1 genes. Knockdown of HIF-1α attenuated the increasing protein levels of both Btg2 and Ndrg1 by hypoxia or L-mimosine in LNCaP cells. Our results indicated that hypoxia and L-mimosine modulated Btg2 and Ndrg1 at the transcriptional level, which is dependent on HIF-1α. L-Mimosine enhanced expression of Btg2 and Ndrg1, which attenuated cell proliferation of the PC-3 and LNCaP prostate carcinoma cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
B-Lymphocytes / cytology
-
B-Lymphocytes / metabolism
-
Carcinoma / drug therapy
-
Carcinoma / genetics
-
Carcinoma / metabolism*
-
Carcinoma / pathology
-
Cell Cycle / drug effects
-
Cell Cycle / genetics
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / metabolism
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cyclin D1 / genetics
-
Cyclin D1 / metabolism
-
Flow Cytometry
-
Gene Expression Regulation, Neoplastic / drug effects*
-
Humans
-
Hypoxia / genetics
-
Hypoxia / metabolism*
-
Hypoxia / pathology
-
Hypoxia-Inducible Factor 1, alpha Subunit / genetics
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Immediate-Early Proteins / genetics
-
Immediate-Early Proteins / metabolism
-
Intracellular Signaling Peptides and Proteins / genetics
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Male
-
Mimosine / pharmacology*
-
Organ Specificity
-
Procollagen-Proline Dioxygenase / antagonists & inhibitors
-
Procollagen-Proline Dioxygenase / genetics
-
Procollagen-Proline Dioxygenase / metabolism
-
Prostate / drug effects*
-
Prostate / metabolism
-
Prostate / pathology
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / genetics
-
Prostatic Neoplasms / metabolism*
-
Prostatic Neoplasms / pathology
-
Signal Transduction / drug effects
-
Transcriptional Activation / drug effects*
-
Transfection
-
Tumor Suppressor Proteins / genetics
-
Tumor Suppressor Proteins / metabolism
Substances
-
CCND1 protein, human
-
Cell Cycle Proteins
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Immediate-Early Proteins
-
Intracellular Signaling Peptides and Proteins
-
N-myc downstream-regulated gene 1 protein
-
Tumor Suppressor Proteins
-
Cyclin D1
-
BTG2 protein, human
-
Mimosine
-
Procollagen-Proline Dioxygenase